Castration-Resistant Prostatic Cancer Clinical Trials

19 clinical trials for Castration-Resistant Prostatic Cancer across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) — RECRUITING · PHASE1
• A Study of MGC026 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) — RECRUITING · PHASE1
• Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer — RECRUITING · PHASE2
• The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma — RECRUITING · PHASE1
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE4
• A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors — TERMINATED · PHASE2
• NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors — TERMINATED · PHASE1
• A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors — COMPLETED · PHASE1
• Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — OTHER
• Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer — TERMINATED · PHASE2
• Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects — COMPLETED · PHASE2
• A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). — TERMINATED · PHASE1
• Safety and Targeting of Anti-hk2 Antibody in mCRPC — TERMINATED · PHASE1
• Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) — OTHER
• Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC — WITHDRAWN · PHASE1
• Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases — COMPLETED
• Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES) — OTHER

Refine this search